Completed PHASE2 INTERVENTIONAL 3-arm NCT00111644

A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia

A Randomized, Double-blind Study of the Effect of Beta-lactam on Treatment Response in Patients Hospitalized With Bacterial Pneumonia

Sponsor: Hoffmann-La Roche

Conditions Pneumonia, Bacterial

Interventions Ceftriaxone beta-lactam

Updated 7 times since 2017 Last updated: Nov 1, 2016 Started: Mar 31, 2005 Primary completion: Jan 31, 2007 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00111644, this PHASE2 trial focuses on Pneumonia, Bacterial and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 7 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Banská Bystrica, Slovakia , Bucharest, Romania , Budapest, Hungary , Buenos Aires, Argentina , Butte, United States , Ciudadela, Argentina , Constanța, Romania , Craiova, Romania , Córdoba, Argentina , Daugavpils, Latvia and 23 more locations